AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
28 mars 2024 16h05 HE | Assembly Biosciences, Inc.
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...
AssemblyBio_logo_RGB.png
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08 févr. 2024 08h00 HE | Assembly Biosciences, Inc.
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....
AssemblyBio_logo_RGB.png
Assembly Biosciences Provides Anticipated Development Milestones for 2024
04 janv. 2024 08h00 HE | Assembly Biosciences, Inc.
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10 nov. 2023 16h05 HE | Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
AssemblyBio_logo_RGB.png
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
10 nov. 2023 08h00 HE | Assembly Biosciences, Inc.
--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability-- SOUTH SAN FRANCISCO, Calif., Nov. 10,...
AssemblyBio_logo_RGB.png
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
08 nov. 2023 16h05 HE | Assembly Biosciences, Inc.
Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical...
AssemblyBio_logo_RGB.png
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
08 nov. 2023 08h00 HE | Assembly Biosciences, Inc.
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
11 oct. 2023 08h00 HE | Assembly Biosciences, Inc.
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
AssemblyBio_logo_RGB.png
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
02 oct. 2023 08h00 HE | Assembly Biosciences, Inc.
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies...
AssemblyBio_logo_RGB.png
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
19 sept. 2023 16h05 HE | Assembly Biosciences, Inc.
-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist...